Women with polycystic ovary syndrome (PCOS) are characterized by defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis. We administered the insulin-sensitizing agent troglitazone to 13 obese women with PCOS and impaired glucose tolerance to determine whether attenuation of hyperinsulinemia ameliorates these defects. All subjects had oligomenorrhea, hirsutism, polycystic ovaries, and hyperandrogenemia. Before and after treatment with troglitazone (400 mg daily for 12 weeks), all had 1) a GnRH agonist (leuprolide) test, 2) a 75-g oral glucose tolerance test, 3) a frequently sampled iv glucose tolerance test to determine the insulin sensitivity index and the acute insulin response to glucose, 4) an oscillatory glucose infusion to assess the ability of the ␤-cell to entrain to glucose as quantitated by the normalized spectral power for the insulin secretion rate, and 5) measures of fibrinolytic capacity [plasminogen activator inhibitor type 1 (PAI-1) and tissue plasminogen activator].
the disposition index (745 Ϯ 135 vs. 381 Ϯ 96; P Ͻ 0.05). The ability of the ␤-cell to appropriately detect and respond to an oscillatory glucose infusion improved significantly after troglitazone treatment; the normalized spectral power for the insulin secretion rate increased to 5.9 Ϯ 1.1 from 4.3 Ϯ 0.8 (P Ͻ 0.05). Basal levels of total testosterone (109.3 Ϯ 15.2 vs. 79.4 Ϯ 9.8 ng/dL; P Ͻ 0.05) and free testosterone (33.3 Ϯ 4.0 vs. 21.2 Ϯ 2.6 pg/mL; P Ͻ 0.01) declined significantly after troglitazone treatment. Leuprolide-stimulated levels of 17-hydroxyprogesterone, androstenedione, and total testosterone were significantly lower posttreatment compared to pretreatment. The reduction in androgen levels occurred independently of any changes in gonadotropin levels. A decreased functional activity of PAI-1 in blood (from 12.7 Ϯ 2.8 to 6.3 Ϯ 1.4 AU/mL P Ͻ 0.05) was associated with a decreased concentration of PAI-1 protein (from 64.9 Ϯ 9.1 to 44.8 Ϯ 6.1 ng/mL; P Ͻ 0.05). No change in the functional activity of tissue plasminogen activator (from 5.3 Ϯ 0.4 to 5.1 Ϯ 0.5 IU/mL) was observed despite a decrease in its concentration (from 9.6 Ϯ 0.9 to 8.2 Ϯ 0.7 ng/mL; P Ͻ 0.05). The marked reduction in PAI-1 could be expected to improve the fibrinolytic response to thrombosis in these subjects.
We conclude that administration of troglitazone to women with PCOS and impaired glucose tolerance ameliorates the metabolic and hormonal derangements characteristic of the syndrome. Troglitazone holds potential as a useful primary or adjunctive treatment for women with PCOS. (J Clin Endocrinol Metab 82: 2108 -2116, 1997) I NSULIN resistance and its concomitant, hyperinsulinemia, are characteristic of women with polycystic ovary syndrome (PCOS) (1) (2) (3) (4) (5) (6) (7) . The insulin resistance is typically profound (2, 5, 7) and acts conjointly with alterations in ␤-cell function (7, 8) to impart a high risk for the development of early-onset noninsulin-dependent diabetes mellitus (NIDDM) (5-7, 9, 10) . Hyperinsulinemia also contributes to the ovarian androgen overproduction in PCOS (11) (12) (13) and may accelerate the development of coronary and other vascular disease (14 -18) in these women. Although the mechanism for accelerated atherosclerosis has not been elucidated in this population, hyperinsulinemia may play an important role, as it has been shown to enhance the production of plasminogen activator inhibitor type 1 (PAI-1) (19 -22) . It follows from these observations that attenuation of hyperinsulinemia may have a salutary effect on the metabolic and hormonal sequelae of PCOS.
Troglitazone is a novel insulin-sensitizing agent that improves oral glucose tolerance and insulin resistance in individuals with impaired glucose tolerance (IGT) (23, 24) . More recently, troglitazone was shown to improve defects in ␤-cell function in subjects with IGT (23) and to lower androgen levels in women with PCOS (25) . This reduction in hyperandrogenemia may result from a reduction in insulin-mediated ovarian androgen production, although this remains speculative. The impact of troglitazone on fibrinolytic capacity has not previously been examined. The present study was thus undertaken to determine whether attenuation of insulin resistance with subsequent reduction of hyperinsulinemia ameliorates abnormalities in insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with PCOS who have IGT.
Materials and Methods

Selection and definition of study subjects
Fifteen women with hyperandrogenemia [plasma free testosterone, Ͼ10 pg/mL (34.6 pmol/L)] (26) and IGT (2 h plasma glucose concentration, 140 -199 mg/dL during OGTT) were recruited. All subjects were anovulatory (cycle length, Ͼ35 days) and had a history of infertility, hirsutism, or acne. The ovarian source of androgen excess was established in all subjects by a dexamethasone androgen suppression test, as previously described (26) . To avoid sample bias, the results of GnRH agonist testing were not used to identify or select subjects. Dexamethasone suppression of androgen levels was considered abnormal if the plasma free testosterone concentration remained elevated [Ն8 pg/mL (27.7 pmol/L)] after the administration of dexamethasone (2 mg daily for 4 days) (26) . Although ultrasound evidence of polycystic ovaries was not used as a diagnostic or inclusion criterion, all subjects had polycystic ovaries by transvaginal ultrasonography using a 5-MHz/90 0 phased array sector vaginal probe (GE RT 3000, General Electric Corp., Milwaukee, WI) (27) .
Exclusion criteria included the use of medications known to alter insulin secretion or action and endocrinopathies, including nonclassic 21-hydroxylase deficiency congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, or thyroid dysfunction. Women with a prior history of gestational diabetes or NIDDM (28) were excluded, as were those who had normal glucose tolerance or NIDDM at baseline oral glucose tolerance testing. A negative screening pregnancy test was required.
The racial/ethnic composition of the study subjects was representative of that of women attending our clinics: eight (62%) were Caucasian, four (31%) were African-American, and one (7%) was Asian. All protocols were approved by the institutional review board of the University of Chicago. Written informed consent was obtained from each subject.
Because of the possible effect of variations in insulin secretion (29, 30) and ovarian function at different phases of the menstrual cycle, women were studied in the follicular phase (days 1-8) of the cycle or after 2 or more months of amenorrhea. After baseline studies (see below) were completed, 400 mg troglitazone were administered orally once daily for 12 weeks, at which time the pretreatment studies were repeated. Compliance with the medication was confirmed by pill count.
Because of the impact of body fat distribution on androgen levels, glucose tolerance, and possibly insulin secretion (31), waist to hip ratios (WHR) were measured, and body composition and fat distribution were assessed by dual energy x-ray absorptiometry scan (32) before and after treatment.
Experimental protocols
Studies were performed after an overnight fast. Intravenous catheters were placed in antecubital veins. Where appropriate, one catheter was used for administration of iv glucose or other secretagogues, whereas the catheter in the contralateral forearm was used for blood sampling. The blood-sampling arm was heated to obtain arterialized venous samples.
GnRH agonist test. Blood samples were obtained before (i.e. at baseline, 20-min intervals, four times) and 0.5, 1, 16, 20, and 24 h after the administration of 10 g/kg leuprolide acetate (TAP Pharmaceuticals, Deerfield, IL). Serum LH and FSH were measured at baseline, 0.5, and 1 h, and steroid hormones were measured at 0, 16, 20, and 24 h. The plasma steroids assayed included total testosterone, estradiol, 17-hydroxyprogesterone, dehydroepiandrosterone (DHEA), androstenedione, and progesterone.
Oral glucose tolerance test (OGTT).
Blood samples were obtained at baseline and at 30-min intervals for 3 h for measurement of glucose and insulin after the ingestion of a 75-g glucose load. Glucose tolerance was evaluated using the criteria of the WHO (28) .
Frequently sampled iv glucose tolerance test (IVGTT).
A frequently sampled IVGTT was performed as previously described by Bergman et al. (33) .
Blood was collected during the IVGTT at Ϫ20, Ϫ15, Ϫ10, Ϫ5, and 0 min, at which time 0.3 g/kg glucose was administered as an iv bolus. 
Insulin secretory responses to oscillatory glucose administration
To determine whether the ability of the ␤-cell to be entrained (i.e. respond to repetitive increases and decreases in glucose with parallel changes in insulin secretion) is affected by troglitazone, a 20% glucose solution was administered in an oscillatory pattern with a period of 144 min, as previously described (34, 35) . This period most effectively brings out defective entrainment of pulsatile insulin secretion by glucose (34) . Samples were drawn every 15 min for the remaining 12 h for the measurement of glucose, insulin, and C peptide.
Measurements of fibrinolytic parameters
Fibrinolytic capacity was characterized by measurement of both the concentration and the functional activity of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in the blood of the subjects at baseline, 6 weeks, and 12 weeks. The mean of the values at 6 and 12 weeks for both t-PA and PAI-1 represents the value during treatment.
Lipid measurements
Serum was obtained for measurement of total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, and triglycerides before and after treatment with troglitazone.
Assay methods
Plasma glucose was measured immediately using a glucose analyzer (YSI model 2300 STAT, Yellow Springs Instruments Co., Yellow Springs, OH). The coefficient of variation of this method is less than 2%. Glycosylated hemoglobin was measured by boronate affinity chromatography with an intraassay coefficient of variation of 4% (Bio-Rad Laboratories, Hercules, CA). Serum insulin was assayed by a double antibody technique (36), with a lower limit of sensitivity of 20 pmol/L and an average intraassay coefficient of variation of 6%. The cross-reactivity of proinsulin in the RIA for insulin is approximately 40%. Plasma C peptide was measured as previously described (37) . The lower limit of sensitivity of the assay is 0.02 pmol/mL, and the intraassay coefficient of variation averaged 6%.
Serum LH and FSH concentrations were measured by fluoroimmunometric assay (Delfia, Wallac, Gaithersburg, MD). The minimal detectable concentration of both LH and FSH was 0.05 U/L. The interassay coefficient of variation was 8% for LH and 5% for FSH. Plasma concentrations of testosterone, estradiol, and DHEA sulfate were measured using kits obtained from Diagnostic Products Corp. (Los Angeles, CA), Pantex (Santa Monica, CA), and Diagnostic Systems (Webster, TX), respectively. The free fraction of plasma testosterone and the concentration of sex hormone-binding globulin (SHBG) were measured by a competitive protein binding assay as previously described (38) . The intra-and interassay coefficients of variation were 3.8% and 8.7%, respectively. Plasma levels of 17-progesterone, androstenedione, and DHEA were determined by RIA after these steroids had been chromatographically purified as previously reported (39) . The precision of these assays averaged 7% (intraassay coefficient of variation) and 12% (interassay coefficient).
The concentrations of t-PA and PAI-1 were determined by enzymelinked immunosorbent assay (Tintelize, Biopool, Ventura, CA) with the use of antibodies that detected t-PA and PAI-1 in both the free and the complexed state. For the determination of PAI-1, the intraassay coefficient of variation was 2.5%, and the interassay coefficient of variation was 3.6%. For determination of t-PA, the intraassay coefficient of variation was 4.3%, and the interassay coefficient of variation was 9.5%. The functional fibrinolytic capacity within an aliquot of plasma was deter-mined with a chromogenic substrate of plasmin as previously described (40, 41) . The functional activity of PAI-1 was determined based on the extent to which an aliquot of plasma inhibited t-PA-induced activation of plasminogen. The plasmin generated was exposed to a chromogenic substrate [S2251, Chromogenix (Pharmacia Hepar), Franklin, OH]. A standard curve was generated with a specific amount of t-PA. One arbitrary unit (AU) of PAI-1 is that amount of PAI-1 able to inhibit 1 IU (based on the WHO standard) of t-PA. In a similar fashion, the concentration of t-PA in plasma was determined with the use of a functional assay based on the ability of an aliquot of sample to induce activation of plasminogen. A colorimetric assay was performed with the chromogenic substrate S2251, and a standard curve was generated with a specific amount of t-PA.
Measurements of total cholesterol, HDL cholesterol, and triglycerides were performed using a Boehringer Mannheim Hitachi 747-100 automated analyzer (Indianapolis, IN).
Data analysis and statistical methods
Summary measures derived from IVGTT. Summary measures derived from the IVGTT included 1) the first phase insulin secretion (AIRg) in response to glucose, calculated as the mean increment above basal of insulin values measured at 2, 3, 4, 5, 6, 8, and 10 min; 2) the insulin sensitivity index (Si), calculated using the MINMOD program provided by Dr. R. N. Bergman (33, 42) (the Si represents the increase in net fractional glucose clearance rate per unit change in plasma insulin concentration after the iv glucose load); and 3) the relationship between the AIRg relative to the degree of insulin resistance (Si), calculated from the equation Z␣ ϭ {ln[(Si ϫ 10 Ϫ5 ) ϫ AIRg)] ϩ 3.802}/0.5613, which defines the relationship for these parameters in normal subjects (43) . The percentile ranking based on the value for Z␣ is obtained from the table of the standard normal distribution. The product of Si and AIRg (disposition index) was also derived and provides a measure of ␤-cell secretory function adjusted for insulin sensitivity, previously described as a constant in any individual (43) .
Determination of insulin secretion rates (ISRs).
Standard kinetic parameters for C peptide clearance were used to derive ISRs. These standard parameters were calculated from 200 decay curves of biosynthetic C peptide obtained in normal, obese, and NIDDM subjects (44) . Age, sex, and body surface area were accounted for. These parameters were derived by application of a two-compartment model of C peptide distribution proposed by Eaton et al. (45) . These parameters were used to derive, in each 15-min interval between blood sampling, the ISR from the plasma C peptide concentrations by deconvolution as previously described (46) . The C peptide profiles were smoothed with a two-point moving average before calculation of the ISRs.
Spectral analysis. Each individual ISR and glucose profile from the oscillatory glucose infusion protocol was submitted to spectral analysis to determine whether the insulin oscillations were entrainable, as previously reported (47, 48) . Each spectrum was normalized assuming the total variance of each series to be 100% and is expressed as the normalized spectral power. Slow trends were removed by the first difference filter before each spectrum was calculated with the window-closing procedure, using a Tukey window with a width of 24 data points, as described by Jenkins and Watts (48) .
Statistical analysis. The significance of differences between pretreatment and posttreatment measures was determined with the use of paired Student's t tests. Logarithmic transformation of data was performed for measures that were not normally distributed. For all analyses, a twotailed P Ͻ 0.05 was considered to indicate statistical significance. Unless otherwise noted, all results are expressed as mean Ϯ sem. Data analysis was performed using StatView 4.5 for the Macintosh (Abacus Concepts, Berkeley, CA).
Results
Clinical characteristics of study subjects
Thirteen subjects completed the protocol. Two subjects were removed from the study before its completion because of noncompliance with testing procedures. All study subjects were obese, and most were markedly so [mean body mass index (BMI), 39.9 Ϯ 1.4 kg/m 2 ; range, 32.0 -47.3 kg/m 2 ; Table  1 ]. Because alterations in body fat distribution can affect insulin sensitivity independently of body weight (49) , precise assessment of regional fat distribution was made by dual energy x-ray absortiometry scan, in addition to the standard waist/hip ratio measure. With the exception of one subject who had a WHR below 0.80, all subjects had the characteristic central obesity of PCOS. Body weight, BMI, and body fat distribution remained stable over the course of the study (Table 1) .
Hormonal and metabolic characteristics of study subjects
Glucose tolerance. All subjects had glycosylated hemoglobin levels below 7.2%, the upper limit of normal (mean, 6.1 Ϯ 0.1%; range, 5.4 -7.0%). After treatment with troglitazone, there was a significant reduction in the level of glycosylated hemoglobin (5.7 Ϯ 0.1 vs. 6.1 Ϯ 0.1%; P Ͻ 0.03) as well as in both the plasma glucose and serum insulin responses to the oral glucose challenge (Fig. 1) . Fasting plasma glucose concentrations declined by an average of 12% (91 Ϯ 3 vs. 103 Ϯ 3 mg/dL; P Ͻ 0.001), whereas the 2 h glucose levels were 15% lower, on the average, after troglitazone treatment (146 Ϯ 8 vs. 171 Ϯ 6 mg/dL; P Ͻ 0.02). The area under the glucose response curve declined similarly by 15% (P Ͻ 0.002). There was a remarkably similar 56% decline in both fasting serum insulin levels (176 Ϯ 22 vs. 397 Ϯ 63 pmol/L; P Ͻ 0.001) and the area under the insulin response curve (P Ͻ 0.001). Eight of 13 (62%) subjects exhibited normal glucose tolerance after treatment, whereas 5 (38%) had persistent, albeit lesser, IGT.
Responses during the frequently sampled IVGTT. Insulin sensitivity and first phase insulin secretory responses to intravenous glucose: Although whole body insulin sensitivity (Si) was profoundly depressed at baseline and remained low after treatment, there was a statistically significant improvement in response to troglitazone administration (0.95 Ϯ 0.26 vs. 0.58 Ϯ 0.14 10 Ϫ5 min Ϫ1 /pmol⅐L; P Ͻ 0.01; Fig. 2 ). By comparison, women with normal glucose tolerance and similar BMI values (32-47 kg/m 2 ) have Si values between approximately 2.0 -5.5 ϫ 10 Ϫ5 min Ϫ1 /pmol⅐L (43) . The improvement in Si in our subjects occurred in the absence of a reduction in weight. The first phase AIRg increased modestly after treatment (876 Ϯ 212 vs. 1161 Ϯ 244 pmol/L), but did not reach statistical significance. However, when the insulin secretory response was analyzed after accounting for the degree of insulin resistance (i.e. disposition index), an improvement in ␤-cell function could be appreciated. That is, the product of Si and AIRg was greater after troglitazone treatment compared to the baseline (745 Ϯ 135 vs. 381 Ϯ 96; P Ͻ 0.05).
Responses to oscillatory glucose administration: During this protocol, the basal insulin secretory rate declined significantly, from 1152 Ϯ 125 pmol/min before treatment to 804 Ϯ 76 pmol/min after treatment (P Ͻ 0.005). The ability of the oscillatory infusion of exogenous glucose to entrain insulin secretion was modestly impaired at baseline, as reflected in a mean value for normalized spectral power similar to that previously reported in subjects with glucose intolerance (7, 34) . The impairment in the ability of the ␤-cell to detect and respond to alterations in plasma glucose concentration improved significantly after troglitazone treatment (5.9 Ϯ 1.1 vs. 4.3 Ϯ 0.8; P Ͻ 0.05; Fig. 3 ).
Androgen and gonadotropin levels: Total testosterone levels, which were markedly elevated at baseline, declined significantly after troglitazone treatment (109.3 Ϯ 15.2 vs. 79.4 Ϯ 9.8 ng/dL; P Ͻ 0.05) as did the levels of free testosterone (33.3 Ϯ 4.0 vs. 21.2 Ϯ 2.6 pg/mL; P Ͻ 0.01). The reduction in free testosterone resulted at least in part from a significant increase in the levels of SHBG (11.7 Ϯ 1.9 vs. 20.0 Ϯ 2.9 nmol/L; P Ͻ 0.01). Leuprolide-stimulated levels of all steroids were significantly lower posttreatment than pretreatment (Table 1) . There was a significant correlation between the change in the leuprolide-stimulated androgen (androstenedione plus testosterone) responses and the change in the area under the insulin response curve during OGTT (r ϭ 0.71; P Ͻ 0.02) and in basal ISRs before and after treatment (r ϭ 0.65; P Ͻ 0.02). The reduction in androgen levels occurred independently of any changes in gonadotropin levels. The LH and FSH levels as well as the ratio of LH to FSH were within the normal range at baseline and did not change after treatment. Likewise, the early LH response to leuprolide was not altered after troglitazone treatment.
Fibrinolytic capacity
Treatment with troglitazone resulted in a 31% reduction in the concentration of PAI-1 protein in blood (44.8 Ϯ 6.1 vs. 64.9 Ϯ 9.1 ng/mL; P Ͻ 0.05) and a 50% reduction in the functional activity of PAI-1 (6.3 Ϯ 1.4 vs. 12.7 Ϯ 2.8 AU/mL; P Ͻ 0.05; Table 1 and Fig. 4 ). There was a significant correlation between the difference in insulin levels during the OGTT before and after treatment and the difference in PAI-1 activity levels pre-and posttreatment (r ϭ 0.61; P Ͻ 0.03).
A more modest reduction (15%) was seen in tPA antigen levels (8.2 Ϯ 0.7 vs. 9.6 Ϯ 0.9 ng/mL; P Ͻ 0.05; Table 1 ). Despite this decrease, the fibrinolytic activity attributable to t-PA in blood did not change after treatment with troglitazone.
Lipid measurements
There was no significant change in levels of total cholesterol, HDL cholesterol, or LDL cholesterol after troglitazone treatment. Although triglyceride levels declined from 164 Ϯ 33 to 115 Ϯ 15 mg/dL, this did not achieve statistical significance.
Discussion
We have found that administration of troglitazone to women with PCOS and IGT results in a marked attenuation of hyperinsulinemia that is associated with improvements in insulin secretion, ovarian androgen biosynthesis, and enhanced fibrinolytic system capacity. Although the precise mechanism of action of troglitazone remains incompletely defined, it appears to enhance insulin action without directly stimulating insulin secretion (50) and acts as a selective ligand for the peroxisome proliferator-activated receptor-␥ (51). Peroxisome proliferator-activated receptor-␥ is a nuclear hormone receptor expressed predominantly in adipose tissue, where it plays a central role in the control of adipocyte gene expression and differentiation (52) (53) (54) (55) .
The results of previous studies have shown that troglitazone attenuates hyperinsulinemia in a number of diverse populations of obese individuals (24) , including women with PCOS (25) . We recently found that troglitazone acts not only to enhance insulin action, but also to ameliorate defects in insulin secretion in subjects with IGT. These combined effects resulted in improved oral glucose tolerance (23) . In the present study, we found a similar improvement in glucose tolerance, as reflected in both a significantly lower concentration of glycosylated hemoglobin after treatment (5.7 Ϯ 0.1 vs. 6.1 Ϯ 0.1%; P Ͻ 0.05) and markedly reduced glucose concentrations throughout an oral glucose tolerance test. As before (23) , this improvement resulted from the effects of troglitazone on both insulin action and insulin secretion. Improvement in insulin action was evidenced by a 30% decline in the basal ISR (P Ͻ 0.02) and a 64% increase (P Ͻ 0.05) in the insulin sensitivity index derived from a frequently sampled IVGTT. It is important to note, however, that although insulin sensitivity improved in response to treatment, it remained profoundly depressed in these subjects and was disproportionate to the degree of obesity, as described previously (2) . Improved ␤-cell function was evidenced by an enhanced ability of the ␤-cell to appropriately secrete insulin in response to an oscillatory infusion of glucose (34) . The latter is expressed quantitatively by the improvement in normalized spectral power for insulin secretion (5.9 Ϯ 1.1 posttreatment vs. 4.3 Ϯ 0.8 pretreatment; P Ͻ 0.05) (34) . Enhanced ␤-cell function was also reflected in results from the IVGTT, which provides an index of ␤-cell function (AIRg) that can be adjusted for the degree of ambient insulin resistance (Si). Because the product of these measures is presumed to be constant (33, 42, 43) , a compensatory decrease in AIRg would be expected to accompany the increase in Si observed after troglitazone treatment. In fact, there was a significant increase in the product of these parameters. We interpret this finding to represent an improvement in ␤-cell function that can be quantified as both the absolute product of these measures as well as the z-score/ percentile rank.
We previously postulated (23) that the improvement in ␤-cell function resulting from troglitazone treatment may result from one of a number of mechanisms. These include reduction in hyperglycemia (i.e. elimination of so-called ␤-cell glucotoxicity) (56 -58) , improvement in insulin resistance, or improvement in lipid parameters. It is also possible that troglitazone may improve defects in insulin secretion through direct actions on the pancreatic ␤-cell (59). Our results do not provide further insights into the mechanisms responsible for the improved ␤-cell function. In the absence of a significant decline in triglyceride levels, however, we can conclude that hypertriglyceridemia is an unlikely explanation. In addition, glucotoxicity seems an implausible explanation, given that fasting plasma glucose and glycosylated hemoglobin concentrations were within the normal range. Although mild hyperglycemia was seen after glucose challenge, such modest alterations in glucose metabolism have not been linked to ␤-cell glucotoxicity.
It is important to note that our current and previous (23) finding of improved ␤-cell function in IGT contrasts with the results of a recent trial of similar design in which women with IGT and a prior history of gestational diabetes were treated with troglitazone (60) . In that study, troglitazone attenuated insulin resistance, but did not improve glucose tolerance or ␤-cell function (60) . The basis for the difference in these results is not obvious, but may relate to the fact that ␤-cell dysfunction was likely to have been present for a protracted period of time in women with a history of gestational diabetes. Alternatively, there may be significant differences in the pathogenetic mechanisms that underlie the insulin secretory dysfunction in these two populations.
In the only previous study in which troglitazone was used to treat women with PCOS, there was no significant im- provement in oral glucose tolerance, despite significant improvements in insulin resistance (25) . It is important to note, however, that nearly two thirds of the subjects enrolled in that trial had normal glucose tolerance at baseline and thus might not be expected to demonstrate significant improvement in glucose tolerance.
It has been shown previously that troglitazone administration lowers plasma androgen levels in women with PCOS in correlatation to a reduction in hyperinsulinemia (25) . However, it was not possible to determine whether ovarian androgen production per se was reduced or, alternatively, whether free androgen concentrations declined because of the insulin-related increase in serum levels of SHBG. We, too, found significant reductions in basal levels of both total and free testosterone that were associated with a significant increase in the concentration of SHBG. In addition, the leuprolide-stimulated levels of total testosterone, androstenedione, 17-hydroxyprogesterone, and DHEA declined significantly after treatment with troglitazone, indicative of decreases in ovarian steroid secretion. Our results are consistent with the hypothesis that insulin modulates the 17-hydroxylase and 17,20-lyase activities of the ovarian steroidforming P450c17 (6, 61) . This enzyme is characteristically abnormally regulated in women with the ovarian androgen excess of PCOS (6, 61) , as evidenced by a characteristic pattern of steroid secretion in response to the endogenous gonadotropin surge induced by a single injection of GnRH agonist (26, 39, (62) (63) (64) (65) . Two lines of evidence suggest that the reduction in leuprolide-stimulated steroid levels results primarily from the reduction in insulin levels. First, there were no changes in either basal or stimulated concentrations of LH or FSH, or in the ratio of LH to FSH after troglitazone treatment, which could account for the attenuated steroidogenic response. Second, there was a significant correlation between the decline in insulin levels and the decline in leuprolidestimulated androgen (androstenedione and testosterone) secretion (r ϭ 0.71; P Ͻ 0.02). Such a correlation was not demonstrable for individual steroids, possibly because the conversion of androstenedione to testosterone is enhanced in PCOS (66, 67) .
Two previous studies have examined the relationship between the reduction of hyperinsulinemia and ovarian steroidogenesis in response to a GnRH agonist (5, 68) . In both cases, metformin was administered to attenuate hyperinsulinemia. Where this was achieved (68) , there was a demonstrable reduction in glucose-stimulated insulin secretion, which correlated with a reduction in leuprolide-stimulated serum levels of 17-hydroxyprogesterone. In the instance in which insulin levels did not decline after metformin treatment (5), there was no decline in ovarian androgen biosynthesis. Although this discordant effect of metformin on hyperinsulinemia cannot readily be explained, taken together, the results from the previous and present studies are consistent with the hypothesis that attenuation of hyperinsulinemia can reduce ovarian steroid production.
Treatment with troglitazone led to decreased concentrations of PAI-1 in blood. A concordant decrease in the activity of PAI-1 in blood was observed. The decrease in the concentration of t-PA in response to troglitazone was not associated with a change in the functional activity of t-PA in the blood of these subjects with PCOS. Although no change in the activity of t-PA was observed under basal conditions, an improved fibrinolytic response to thrombosis could be anticipated because of the substantial decrease in the concentration and activity of PAI-1 after treatment with troglitazone. Accordingly, treatment with troglitazone improves the fibrinolytic capacity in the blood of these subjects with insulin resistance.
Increased concentrations of PAI-1 have been observed in subjects with insulin-resistant states, including diabetes (69), obesity (70) , hypertension (71) , and PCOS (15, 72) . Weight loss (70, 73) and treatment with metformin (74) have both been shown to decrease circulating concentrations of insulin as well as PAI-1. Insulin has been shown to directly augment expression of PAI-1 in vivo and in vitro (19, 22, 75) . We have recently reported a synergistic interaction between insulin and triglyceride associated with very low density lipoprotein (20) . The positive correlation between the reduced secretion of insulin in response to glucose and the decreased plasma concentration of PAI-1 after treatment with troglitazone (r ϭ 0.61; P Ͻ 0.03) is consistent with the proposed direct role of insulin in modulating expression of PAI-1. In the subjects with PCOS reported here, the combination of a reduction in the secretion of insulin and the decreased concentrations of triglyceride in plasma after treatment with troglitazone is likely to account for the reduction in blood concentrations of PAI-1 observed.
In summary, we have found that administration of troglitazone to women with PCOS and IGT ameliorates each of the metabolic and hormonal derangements that characterize these women. Given the high prevalence of the disorder (6) and the significant risk it imparts for the development of glucose intolerance (5-7, 9) and cardiovascular morbidity and mortality (14 -18) , troglitazone may prove to be a useful adjunct in the treatment of women with PCOS.
